S&P TSX Capped Composite...

US Dollar vs CAD

Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

Get Started

ZVSA ZyVersa Therapeutics Inc

3.88

0.00 (0.00%)

Pre Market

Last Updated: 03:46:39

Delayed by 15 minutes

Form EFFECT - Notice of Effectiveness

ZyVersa Therapeutics (NASDAQ:ZVSA)
Historical Stock Chart
From Jun 2024 to Jul 2024

Click Here for more ZyVersa Therapeutics Charts.

ZyVersa Therapeutics (NASDAQ:ZVSA)
Historical Stock Chart
From Jul 2023 to Jul 2024

Click Here for more ZyVersa Therapeutics Charts.

ZyVersa Therapeutics Inc News

Form 4 - Statement of changes in beneficial ownership of securities
Thursday 18 July 2024 (8 hours ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Thursday 18 July 2024 (8 hours ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Thursday 18 July 2024 (8 hours ago) • Edgar (US Regulatory)

ZyVersa Therapeutics Announces Publication Demonstrating that Inflammasome ASC Inhibitor IC 100 Restored Retinal Structure and Function in a Retinopathy of Prematurity Animal Model
Thursday 18 July 2024 (18 hours ago) • GlobeNewswire Inc.

Form EFFECT - Notice of Effectiveness
Tuesday 16 July 2024 (2 days ago) • Edgar (US Regulatory)

ZyVersa Therapeutics' CEO, Stephen C. Glover, Is an Invited Speaker at H.C. Wainwright 3rd Annual Kidney Conference to be Held Virtually on July 15, 2024
Tuesday 9 July 2024 (1 week ago) • GlobeNewswire Inc.

ZyVersa Therapeutics Reports First Quarter, 2024 Financial Results and Provides Business Update
Wednesday 15 May 2024 (2 months ago) • GlobeNewswire Inc.

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Wednesday 15 May 2024 (2 months ago) • Edgar (US Regulatory)

Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]
Wednesday 15 May 2024 (2 months ago) • Edgar (US Regulatory)

ZyVersa Therapeutics' CEO, Stephen C. Glover, to Participate in the 2024 BIO International Convention
Tuesday 14 May 2024 (2 months ago) • GlobeNewswire Inc.

ZyVersa Therapeutics Announces Publication Reinforcing the Rationale for Inhibiting ASC with IC 100 to Potentially Attenuate Cardiac Comorbidities in Patients with Alzheimer’s Disease
Monday 29 April 2024 (3 months ago) • GlobeNewswire Inc.

ZyVersa Therapeutics Highlights Published Data Demonstrating NLRP3 Inflammasome Inhibition Has Potential to Decrease Atherosclerotic Lesions in Patients with Diabetes
Thursday 4 April 2024 (3 months ago) • GlobeNewswire Inc.

More ZyVersa Therapeutics Inc News Articles

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions